Company intelligence / Profile preview

Cryoviva

Gurugram, Haryana, India

Ownership: Private
Development stage: Other

Overview

Cryoviva has successfully released 33 cryopreserved cord blood units for both autologous and allogeneic therapy in diseases such as leukemia, autism, cerebral palsy, and thalassemia. Two releases were used at Duke University for FDA-approved autism clinical trials. The company is active and focuses on umbilical cord blood and tissue stem cell banking in India and internationally.

Therapeutic areas: ImmunologyNeurologyMetabolic DisordersHematologyPsychiatryOncology
Modalities: Stem cell therapyCell therapyMesenchymal stromal cell therapyBiologic
Industry: Non-Drug Biotech

Partnerships

Da Vinci Biosciences (technology licensing partner for MSC culture methods)[1]Duke University (clinical trial participation for autism therapy with cord blood)[1]

Beyond the preview

Go deeper on Cryoviva.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cryoviva.

Explore the full profile